Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Update

Astria Therapeutics, Inc. (NASDAQ:ATXSGet Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,010,000 shares, an increase of 18.2% from the February 29th total of 1,700,000 shares. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 4.5% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ATXS shares. Jefferies Financial Group lifted their price objective on shares of Astria Therapeutics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 25th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Astria Therapeutics in a research note on Monday, March 25th. Finally, Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 26th.

Check Out Our Latest Stock Analysis on Astria Therapeutics

Insider Activity at Astria Therapeutics

In other news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the stock in a transaction on Thursday, February 1st. The stock was purchased at an average price of $12.09 per share, for a total transaction of $29,999,521.50. Following the acquisition, the director now owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the stock in a transaction on Thursday, February 1st. The stock was purchased at an average price of $12.09 per share, for a total transaction of $29,999,521.50. Following the acquisition, the director now owns 4,873,721 shares in the company, valued at $58,923,286.89. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Christopher Morabito sold 9,200 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc raised its stake in Astria Therapeutics by 34.4% in the 4th quarter. Legal & General Group Plc now owns 3,492 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 894 shares during the period. Bank of America Corp DE raised its stake in Astria Therapeutics by 18.4% in the 1st quarter. Bank of America Corp DE now owns 13,162 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 2,050 shares during the period. Nuveen Asset Management LLC raised its stake in Astria Therapeutics by 2.3% in the 4th quarter. Nuveen Asset Management LLC now owns 102,166 shares of the biotechnology company’s stock valued at $785,000 after acquiring an additional 2,290 shares during the period. UBS Group AG raised its stake in Astria Therapeutics by 66,700.0% in the 1st quarter. UBS Group AG now owns 2,672 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,668 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Astria Therapeutics by 416.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 2,707 shares during the period. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Stock Up 3.5 %

ATXS opened at $14.08 on Friday. The firm’s fifty day moving average price is $13.80 and its two-hundred day moving average price is $8.83. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90.

Astria Therapeutics (NASDAQ:ATXSGet Free Report) last posted its quarterly earnings data on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). Sell-side analysts predict that Astria Therapeutics will post -1.55 EPS for the current fiscal year.

Astria Therapeutics Company Profile

(Get Free Report)

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

Recommended Stories

Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.